IN BRIEF: ValiRx Extends Collaboration Agreement With Physiomics
IN BRIEF: ValiRx Extends Collaboration Agreement With Physiomics
Read moreThu, 19th May 2016 15:44
IN BRIEF: ValiRx Extends Collaboration Agreement With Physiomics
Read moreIN BRIEF: ValiRx's VAL201 Patented For Treatment Of Metastatic Cancer
Read moreUK TRADING UPDATE SUMMARY: Newly-Listed Wheaton Reports Bumper Quarter
Read moreUK TRADING UPDATE SUMMARY: Joules In Lockdown Hit But Online Surges
Read moreValiRx Loss Narrows In First Half Amid Reduction In Expenses
Read moreIN BRIEF: ValiRx Raises GBP300,700 From Broker Option
Read moreUK TRADING UPDATE SUMMARY: Gear4music Strikes Right Note As Sales Jump
Read moreUK Shareholder Meetings Calendar - Next 7 Days
Read moreIN BRIEF: ValiRx Outlines Oncology, Women's Health Focus
Read more(Sharecast News) - Medicines developer ValiRx said on Monday that it was looking to build on its existing portfolio of drug candidates and grow a pipeline of innovative, early-stage projects in the areas of oncology and women's health.
Read moreIN BRIEF: ValiRx Annual Loss Narrows As Expenses Fall
Read moreIN BRIEF: ValiRx Cuts Pay By Two Thirds; Terminates GeneICE Agreement
Read moreValiRx Delays Annual Results Amid Covid-19 Pandemic
Read moreUK TRADING UPDATE SUMMARY: Novacyt Virus Test Orders At EUR135 Million
Read more(Sharecast News) - Biotechnology oncology company ValiRx has entered into a collaboration agreement with Oncolytika and Black Cat Bio to explore the use of VAL201 in a combination treatment for patients suffering a hyperimmune response to Covid-19.
Read more